Published • loading... • Updated
China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion
The partnership will use InnoCare's drug discovery platform to pursue compounds against up to five targets, with $3.25 billion tied to milestones.
- On Thursday, InnoCare Pharma announced a research collaboration and licensing agreement with Eli Lilly worth up to about $3.35 billion to discover and advance compounds against up to five targets.
- The Beijing-based firm specializes in cancer and autoimmune disease treatments, leveraging its proprietary drug discovery platform to underpin the new partnership with Eli Lilly.
- Financial terms include up to $100 million in upfront and near-term payments, plus about $3.25 billion in development and commercial milestone payments with tiered, single-digit royalties on future sales.
- A spokesperson for Eli Lilly did not immediately respond to requests for comment regarding which specific disease areas would be targeted in the collaboration.
- Observers must monitor future regulatory filings to determine the collaboration's scope, as the specific therapeutic targets and disease areas remain undisclosed by both companies.
Insights by Ground AI
21 Articles
21 Articles
Eli Lilly (NYSE: LLY), Novo Nordisk And Novartis Bet On Discovery Platforms Over Late-Stage Pipeline Assets
Big pharma’s dealmaking appetite remains strong in 2026, but the strategic logic has shifted decisively toward platform access over outright company acquisitions. Eli Lilly & Co (NYSE: LLY) and China’s InnoCare Pharma signed a research collaboration and license agreement on Thursday covering up to five undisclosed targets across cancer and autoimmune disease. InnoCare is eligible […]
Coverage Details
Total News Sources21
Leaning Left2Leaning Right3Center8Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
15%
C 62%
R 23%
Factuality
To view factuality data please Upgrade to Premium
